natgillin/translations-raw huggingface dataset:
It has been recently discovered that any amount of unprotected exposure can potentially cause immune system suppression and lead to future health problems, such as skin carcinomas and other dermatological disorders. 
Nedavno je otkriveno da bilo koja količina nezaštićenog izlaganja može potencijalno izazvati supresiju imunološkog sustava i dovesti do budućih zdravstvenih problema, kao što su karcinomi kože i drugi dermatološki poremećaji.
The method according to claim 1, wherein R2 is selected from the group consisting of halogen, cyano, C1-6-alk(en/yn)yl, halo-C1-6-alk(en/yn)yl, C1-6-alk(en/yn)yloxy, optionally substituted phenyl and optionally substituted pyridyl. 
Spoj prema bilo kojem od patentnih zahtjeva 1-13, naznačen time što je R2 izabran iz grupe koju čine halogen, cijano, C,.s-alk(en/in)il, halo-C; .s-alk(en/in)il, C;.s-alk(en/injiloksi, izborno supstituirani fenil i izborno supstituirani piridil.
disintegrant: 1-20% by weight 
- sredstvo za raspadanje: 1-20%, težinski
The polypeptide for use according to claim 1 or 2, wherein the polypeptide exhibits a fibrinolytic activity that is inhibited by a2-antiplasmin at a rate of inhibition that is at least about 5-fold faster than the rate of inhibition of the fibrinolytic activity of mini-plasmin by a2-antiplasmin. 
Polinukleotid enkodiran uz pomoć nukleinske kiseline, naznačen time da je prema bilo kojem od zahtjeva 1 do 7. Polipeptid prema zahtjevu 8, naznačen time da polipeptid pokazuje fibrinolitičku aktivnost koja je inhibirana s a2-antiplazminom pri stupnju inhibicije koji je najmanje oko 5 puta brži nego što je stupanj inhibicije fibrinolitičke aktivnosti mini-plazmina sa a2-antiplazminom.
The following compounds were synthesized according to the above procedure. 
Sljedeće spojeve sintetizira se postupkom opisanim gore.
sulfur donors, antimycotic agents, antibiotic agents, anti-inflammatory agents, antiseptic agents and/or local anaesthetic agents. 
donore sumpora, antimikotike, antibiotike, protuupalne agense, antiseptičke agense i/ili lokalne anestetike.
The method according to at least one of claim 7, wherein both, the dimensionally stable portion and also the portion which is soluble in gastric juice contain a further active ingredient. 
Ljekoviti oblik u skladu s najmanje jednim od prethodnih patentnih zahtjeva, naznačen time što se dodatni aktivni sastojak nalazi kako u dimenzijski stabilnom dijelu tako i u dijelu topljivom u želučanom soku.
The method of claim 10, wherein the bacterial infection is caused by Clostridium difficile. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 11 ili 12, naznačen time što je bakterijska infekcija infekcija bakterijom Clostridium difficile.
a light chain variable amino acid sequence of SEQ ID NO: 18 and a heavy chain variable amino acid sequence of SEQ ID NO: 13; or 
(1) varijabilnu sekvencu aminokiselina laganog lanca SEQ ID NO: 18 1 varijabilnu sekvencu aminokiselina teškog lanca $EQ ID NO: 13; ili
Z is CH=CH or S; and each Q is independently phenyl or pyridinyl, each optionally substituted with up to 3 substituents independently selected from the group consisting of halogen, cyano, C1-C4 alkyl, C1-C4 haloakyl, C1-C4 alkoxy and C1-C4 haloalkoxy; 
Zje CH=CH ili S; i svako Q je nezavisno fenil ili piridinil, svaki izborno supstituiran sa do 3 supstituenta nezavisno izabrana iz grupe koju čine halogen, cijano, Cy-C4 alkil, C,-Ca haloalkil, Cy-C4 alkoksi and C,-C4 haloalkoksi; i
The nanoparticle of any one of aspects 22-25, wherein the nucleic acid is from about 2 to about 40 nucleotides in length. 
duljine oko 2 do oko 40 nukleotida; ii) do 100 nukleotida; ili iii) više od 100 nukleotida.
with prop-2-en-1-ol in the presence of a palladium catalyst and a base; wherein X3 is chloro, bromo, or iodo. 
S prop-2-en-1-olom u prisutnosti paladijevog katalizatora i baze; pri čemu X; je klor, brom, ili jod, ili
wherein said antibody or antigen binding fragment thereof specifically binds to at least one of Ang1 and Ang2 ligands of Tie 2 receptor. 
pri čemu se spomenuto antitijelo ili njegov antigen-vežući fragment specifično veže za najmanje jedan od Ang-1 i Ang-2 liganda Tie-2 receptora.
Sugar replacement composition, according to a first specific embodiment of the invention. Ingredient Minimum relative amount (Weight %) 
Sastavina koja zamjenjuje šećer, prema prvoj varijanti, koja nije u skladu s ovim izumom Minimalna relativna Maksimalna relativna
adding (ii) at least one transition metal ionic compound, whereby insoluble matter is generated from organic chemicals. 
(1i) dodavanje (1i) barem jednog ionskog spoja prijelaznog metala, pri čemu se netopiva tvar generira iz organskih kemikalija.
a VL CDR3 having the amino acid sequence of SEQ ID NO: 70. 
varijabilnu domenu lakog lanca koja ima sekvencu aminokiseline od SEQ ID br. 77.
The composition for use according to claim 12, wherein said depressive disorder is major depressive disorder. 
Pripravak za uporabu sukladno patentnom zahtjevu 10, naznačeno time, da je navedeni depresivni poremećaj klinička depresija.
The method according to claim 6, wherein the outer pipe having an outer diameter of more than 60 mm and a wall thickness of less than 3 mm is used to carry out the method. The method according to claim 6, wherein the outer pipe having an outer diameter of more than 60 mm and a wall thickness of less than 2.7 mm is used to carry out the method. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se za provođenje postupka upotrebljava cijev s vanjskim promjerom većim od 60 mm i debljinom stijenke manjom od 3 mm, osobito s debljinom stijenke manjom od 2,7 mm.
The fusion protein according to claim 4, in which a sequence recognized by metalloprotease MMP is Pro Leu Gly Leu Ala Gly, a sequence recognized by urokinase uPA is Arg Val Val Arg, a sequence recognized by furin is Arg Lys Lys Arg, and a sequence recognized by native furin is Arg His Arg Gln Pro Arg Gly Trp Glu Gln Leu or His Arg Gln Pro Arg Gly Trp Glu Gln. 
Fuzijski protein prema zahtjevu 4, naznačen time da sekvenca koju prepoznaje metaloproteaza MMP je Pro Leu Gly Leu Ala Gly, sekvenca koju prepoznaje urokinaza uPA je Arg Val Val Arg, sekvenca koju prepoznaje furin je Arg Lys Lys Arg, i sekvenca koju prepoznaje izvorni furin je Arg His Arg Gln Pro Arg Gly Trp Glu Gln Leu ili His Arg Gln Pro Arg Gly Trp Glu Gln.
A process as in Claim 9, wherein the compound of formula (VIII-S) is present in an amount in the range of from about 0.8 to about 1.25 molar equivalents. 
Postupak kao u patentnom zahtjevu 9, naznačen time da je spoj formule (VIII-S) prisutan u količini u rasponu od oko 0.8 do oko 1.25 molarnih ekvivalenata.
This invention relates to a compound of general Formula I and pharmaceutically acceptable enantiomers, salts or solvates thereof, wherein: 
PATENTNI ZAHTJEVI Spoj Formule Ib: i njegova farmaceutski prihvatljiv enantiomer, sol ili solvat, pri čemu:
treating an immune-based disease in a patient, wherein said immune-based disease is rheumatoid arthritis, allergy, asthma, glomerulonephritis, lupus, or inflammation related to any of the aforementioned; or treating a cancer in a patient; or 
Spoj za upotrebu prema patentnom zahtjevu 45, naznačen time, što navedeno oboljenje u čijoj je osnovi poremećaj imunog sistema označava reumatoidni artritis, alergiju, astmu, glomerulonefritis, lupus ili inflamaciju koja prati bilo koje od prethodno navedenih oboljenja.
wherein the acyl groups are selected from the group consisting of substituted or unsubstituted C2-6 aliphatic acyl groups, substituted or unsubstituted benzoyl group, a-naphthoyl group, or B-naphthoyl group and C3-6 cycloalkyl carbonyl groups, wherein the substituents of substituted C2-6 aliphatic acyl groups or the substituted benzoyl group, a-naphthoyl group, or B-naphthoyl group are 1 to 3 substituents selected from a C1-6 linear or branched alkyl group, a C1-6 linear or branched alkoxy group, a halogen atom, a nitro group, and a carboxy group; 
-6-cikloalkilkarbonil-skupine, pri čemu su supstituenti od supstituiranih alifatskih C2-6-acil-skupina, ili od supstituirane benzoil-skupine, a-naftoil-skupine, ili B-naftoil-skupine, jedan do tri supstituenta odabrana od sljedećih: ravnolančana ili razgranata C1-6-alkil-skupina, ravnolančana ili razgranata C1-6-alkoksi-skupina, atom halogena, nitro-skupina i karboksi-skupina; dok su supstituenti od supstituirane ravnolančane ili razgranate C1-6-alkil-skupine, jedan do tri supstituenta odabrana iz skupine koju čine: atom halogena i ravnolančana ili razgranata C1-6-alkoksi-skupina;
The salt according to embodiment 17, which salt is selected from the hydrogen adipate salt, the lactate salt, the hydrogen maleate salt, the hydrogen fumarate salt and the hydrogen succinate salt of the compound of formula [I]. 
Sol spoja formule [1] sol koja je odabrana između soli vodikovog adipata, vodikove malonatne soli, vodikove fumaratne soli, vodikove sukcinatne soli, benzen-sulfonatne soli, vodikove maleatne soli i salicilatne soli spoja formule [1].
Preventive and curative effect on atherogenesis in rabbits fed on high cholesterol diet 
Preventivan i kurativan učinak na aterogenezu u zečevima hranjenim s visokom kolesterolnom dijetom
A method for the prophylaxis or treatment of infection by HIV or for the prophylaxis, treatment, or delay in the onset of AIDS in a subject in need thereof which comprises administering to the subject an effective amount of the compound according to claim 1 or a pharmaceutically acceptable salt thereof. 
Kombinacija prema bilo kojem od patentnih zahtjeva 1-4, za uporabu u profilaksi infekcije HIV-om ili profilaksi SIDA-e kod subjekta. Kombinacija prema bilo kojem od patentnih zahtjeva 1-4, za uporabu u liječenju infekcije HIV-om, liječenju SIDA-e, ili odlaganju početka SIDA-e kod subjekta.
R2′ is hydrogen; (C1-C4)alkyl optionally substituted with a (C1-C4)alkoxy; or a phenyl group, the phenyl group being optionally substituted with a (C1-C4)alkoxy group; 
R? je vodik; (C;-Cy)alkil koji može biti supstituiran s (Ci-Cxg)alkoksi; ili fenilnom skupinom, fenilna skupina koja može biti supstituirana s (C,-Cg)alkoksi-skupinom;
In one embodiment, the antibody comprises: a heavy chain variable region CDR1 of SEQ ID NO: 3; a heavy chain variable region CDR2 of SEQ ID NO: 17; a heavy chain variable region CDR3 of SEQ ID NO: 31; a light chain variable region CDR1 of SEQ ID NO: 45; a light chain variable region CDR2 of SEQ ID NO: 59; and a light chain variable region CDR3 of SEQ ID NO: 73. 
(c) CDRI varijabilnog područja jakog lanca sa SEQ ID NO: 3; CDR2 varijabilnog područja jakog lanca sa SEQ ID NO: 17; CDR3 varijabilnog područja jakog lanca sa SEQ ID NO: 31; CDRI varijabilnog područja slabog lanca sa SEQ ID NO: 45; CDR2 varijabilnog područja slabog lanca sa SEQ ID NO: 59; i CDR3 varijabilnog područja slabog lanca sa SEQ ID NO: 73;
R4, R5 n and m variants of Set D are depicted as a fragment of formula I (for example, the depiction represents a compound of formula I wherein R4 is methyl, R5 is O, n is single bond and m is double bond). 
» dijelovi formule I (npr., prikaz o predstavlja spoj formule I gdje je R" metil, R* je 0, n je jednostruka veza i m je dvostruka veza).
The mixture was filtered through celite, the celite was washed with ethyl acetate, and the combined organic solvents were concentrated in vacuo. 
Smjesa se filtrira kroz celit, celit se ispere etilacetatom, a spojeno organsko otapalo se koncentrira uz podtlak.
An isolated human antibody or antigen-binding fragment thereof that specifically binds human angiopoietin-2 (hAng2) with a KD of less than 80 pM but does not exhibit any binding to hAng-1 when tested in a surface plasmon resonance assay and that comprises a heavy chain CDR-1 (HCDR1) having the amino acid sequence of SEQ ID NO:4, an HCDR-2 having the amino acid sequence of SEQ ID NO:6, an HCDR-3 having the amino acid sequence of SEQ ID NO:8, a light chain CDR-1 (LCDR-1) having the amino acid sequence of SEQ ID NO:12, an LCDR-2 having the amino acid sequence of SEQ ID NO:14, and an LCDR-3 having the amino acid sequence of SEQ ID NO:16. 
HR P20161043 T1 PATENTNI ZAHTJEVI Izolirani ljudsko antitijelo ili fragment koji vezuje njegov antigen koji se konkretno vezuje za ljudski angiopoietin-2 (hAng2) uz Kp manji od 80 pM, ali ne ispoljava nikakvo vezivanje za hAng-1 kada se ispituje u testu rezonancije površinskih plazmona i koji se sastoji od CDR-I teškog lanca (HCDRI) sa sekvencijom aminokiseline SEQ ID NO:4, HCDR-2 sa sekvencijom aminokiseline SEQ ID NO:6 1 HCDR-3 sa sekvencijom aminokiseline SEQ ID NO:8, CDR-1 lakog lanca (LCDR-1) sa sekvencijom aminokiseline SEQ ID NO:12, LCDR-2 sa sekvencijom aminokiseline SEQ ID NO:14 i LCDR-3 sa sekvencijom aminokiseline SEQ ID NO:16.
ff. 005-C04-48-1 comprises a variable heavy chain domain corresponding to a nucleic acid sequence according to SEQ ID NO: 405, and an amino acid sequence according to SEQ ID NO: 217, and a variable light chain domain with a nucleic acid sequence according to SEQ ID NO: 477, and an amino acid sequence according to SEQ ID NO: 289, 
-H08-48-5 sadrži promjenjivu domenu teškog lanca koja odgovara sekvenci nukleinske kiseline u skladu sa SEQ ID NO: 347, te sekvencu nukleinske kiseline u skladu sa SEQ ID NO: 159. i promjenjivu domenu lakog lanca sa sekvencom nukleinske kiseline u skladu sa SEQ ID NO: 369, te sekvencu nukleinske kiseline u skladu sa SEQ ID NO: 181,
A pharmaceutical composition comprising the compound of any one of claims 1 to 3, the conjugate of claim 6 or 7, the nucleic acid molecule or the set of nucleic acid molecules according to claim 8, or the vector or the set of vectors of claim 9 and a pharmaceutically acceptable carrier. 
Farmaceutski pripravak koji sadrži spoj prema bilo kojem od zahtjeva 1 do 3, konjugat prema zahtjevu 6 ili 7, molekulu nukleinske kiseline ili set molekula nukleinske kiseline prema zahtjevu 8 ili vektor ili set vektora prema zahtjevu 9 i farmaceutski prihvatljiv nosač.
0.05 The solution for peritoneal dialysis having the following composition 
Otopina za peritonealnu dijalizu, naznačena time što ima sljedeći sastav:
reacting the compound of formula VII with sodium acetate to produce a compound of formula VI 
b) reakcija spoja formule VII s natrijevim acetatom, da se proizvode spoj formule VI:
Combination of R,R-glycopyrrolate, rolipram and budesonide or their physiologically acceptable salts for use in the treatment of inflammatory diseases. 
Kombinacija R.R-glikopirolata roliprama i budesonida ili njihovih fiziološki prihvatljivih soli, naznačena time, da se koristi za liječenje upalnih oboljenja.
The preferred basic organic component of the present OMB fertilizer is an organic substance comprising humic acids that are identical or analogous to the humic acids in the humus of the soil and possess a porous structure. 
Ponajprije osnovna organska komponenta OMB gnojiva je organska tvar koja sadrži huminske kiseline, koje su jednake ili slične huminskim kiselinama u humusu tla, pri čemu imaju poroznu strukturu.
#30. A method according to aspect #8 or aspect #29, wherein the amount of base added is more than sufficient to fully neutralise the polycarboxylic acid polymer. 
Postupak za koji se traži zaštita patentom u patentnom zahtjevu 13, ili patentnom zahtjevu 14, pri čemu je dodana količina baze više nego dovoljna da potpuno neutralizira polimer polikarboksilne kiseline.
Arousal: very low, stupor, coma, little or no responsiveness 
: vrlo niska, stupor, koma, malo ili nimalo odgovora na podražaj
an antibody against CD20. 
- protutijelo protiv CD20.
The method of claim 52, wherein the tauopathy is progressive supranuclear palsy. 
Antitijelo ili farmaceutski pripravak za uporabu prema zahtjevu 17, pri čemu tauopatija je progresivna supranuklearna paraliza.
Compound 38 was obtained as an oil from compound 37 by method F. 
Spoj 38 se dobiva kao ulje iz spoja 37 pomoću postupka F.
female hooded-Lister rats (Harlan, UK) were used as subjects for these studies. 
50 ženki,,hooded"-Lister štakora (Harlan, UK) je korišteno kao subjekt za ova proučavanja.
The chimeric peptide for use of claim 25, wherein said supplementary therapy is administered prior to, contemporaneously with or following the administration of the chimeric peptide. 
Himerni peptid za uporabu u skladu s patentnim zahtjevom 25, naznačen time što se spomenuta dopunska terapija daje prije, istovremeno sa ili nakon primjene himernog peptida.
introducing at least one inlet for injection material, which inlet ends at the first side of the assembly, connecting the space which is enclosed by the cover layer and the mould to a discharge, 
- < uvođenje barem jednog ulaza (11) za injciranje materijala, taj ulaz završava na prvoj strani sklopa (3),
A dispenser according to claim 1 or 2, wherein the first ring member comprises an engaging portion arranged to co-operate with the engaging portion of the limiting member to limit free rotation of the first ring member relative to the limiting member about the axis. 
Dispenzer u skladu sa patentnim zahtjevom 18 ili 19, gdje prvi prstenasti element (202, 1610) sadrži dio (1630) za angažiranje koji je razmješten da surađuje sa dijelom za angažiranje (1620) elementa (1602) za ograničavanje da bi se ograničila slobodna rotacija prvog prstenastog elementa u odnosu na element za ograničavanje oko osi.
The variant ActRIIB protein of any preceding claim, wherein at least one alteration with respect to the sequence of SEQ ID NO: 2 is a conservative alteration positioned within the ligand binding pocket. 
Varijantni ActRIIB protein iz bilo kojeg od prethodnih zahtjeva, naznačen time, što protein sadrži D ili E na poziciji koja odgovara poziciji 79 SEQ ID NO:2.
wherein: and R2, the same or different, represent a hydrogen atom, or they are selected from linear or branched C1-C20 alkyl groups optionally halogenated, cycloalkyl groups optionally substituted; or aryl groups optionally substituted; 
Ri i R,, isti ili različiti, predstavljaju atom vodika, ili su izabrani od linearnih ili granatih C;-C> alkil grupa koje su izborno halogenirane, cikloalkil grupa koje su izborno supstituirane; aril grupa koje su izborno supstituirane;
An apparatus for decoding an image, the apparatus comprising: an encoding information extractor which extracts split information indicating whether to split a coding unit of an upper depth into coding units of deeper depths and skip information indicating whether a prediction mode of a current coding unit is a skip mode, from the image data; and 
Postupak za dekodiranje slike, te postupak sadrži: izvlačenje informacija o maksimalnoj veličini jedinice kodiranja, i informacije o razdvajanju koja pokazuje da li treba podijeliti jedinicu kodiranja dubine i, gdje je i cijeli broj, u jedinice kodiranja dubine i+1, iz toka bitova uključujući kodirane podatke iz slike;
An isolated nucleic acid vector comprising the isolated nucleic acid molecule according to embodiment 52. 
7. Izolirana molekula nukleinske kiseline prema zahtjevu 6 naznačena time što se sastoji od:
is CHF2, CF3, H, F, Cl, or R1 and R2 may be taken together with their attached ring A to form a fused ring system selected from the group consisting of naphthalenyl, and isoquinolinyl; provided that R2 may not be H if R1 is H; 
R'je CHF,, CF4, H, F, CI, HR P20190174 T1 E Sla - u Da, ili R'i R* mogu biti uzeti zajedno s enom A za skoj su voza da tvore spojeni prstenasti sustav odabran iz skupine koju čine naftalenil, i izokinolinil; pod uvjetom da R?nije H ukoliko R/ je H;
remainder water. Suspension concentrate according to any of the above claims 1 to 7, wherein the anti-freeze compound is selected from the list of propylene glycol, urea, glycerol, ethylene glycol, diethylene glycol, triethylene glycol, dipropylene glycol and tripropyleneglycol. 
Koncentrat otopine u skladu s bilo kojim od prethodnih patentnih zahtjeva 1 do 6, pri čemu je sredstvo protiv zamrzavanja odabrano s liste propilenglikola, ureje, glicerola, etilenglikola, dietilenglikola, trietilengliola, dipropilenglikola i tripropilenglikola.
A dimer comprising two polypeptides of claim 10, wherein the two polypeptides are dimerized via disulfide bridges of the third peptide linkers. An isolated nucleic acid molecule encoding the fusion polypeptide of claim 1 . 
Molekula nukleinske kiseline koja kodira fuzijski polipeptid bilo kojeg zahtjeva 1-8, poželjno u operativnom spoju sa slijedom za kontrolu ekspresije.
The entire aorta was removed 1 or 2 cm into the iliac arteries and fixed in buffer phosphate 0.1 M (pH 7.4) with glutaraldehyde (4%). 
Odstranjena je cijela aorta 1 ili samo 2 cm bolesne arterije i fiksirana u fosfatanom puferu 0,1 M (pH 7,4) s glutaraldehidom (4%).
The system of claim 46, wherein the waste constituents of the first type consists essentially of mixed plastic. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time, da se prva odabrana komponenta sastoji u biti od mješovitog plastičnog materijala.
An epoxy-tigliane compound or a pharmaceutically acceptable salt thereof for use according to any one of claims 1 to 6 wherein R1 is hydrogen and R2 is OH or -OC(O)C1-6alkyl, -OC(O)C2-6alkenyl or -OC(O)C2-6alkynyl, or R1 and R2 together form a carbonyl group. 
Epoksi-tiglianski spoj ili njegova farmaceutski prihvatljiva sol za uporabu sukladno bilo kojem od zahtjeva 1 do 6, pri čemu je R1 vodik i R2 je OH ili -OC(O)C1-6alkil, -OC(O)C2-6alkenil ili -OC(O)C2-6alkinil, ili R1 i R2 zajedno tvore karbonil skupinu.
and a second polypeptide chain has a structure represented by the formula: VH2-L3-VH1-L4-CH1 [II] 
[1] i drugi polipeptidni lanac ima strukturu predstavljenu s formulom: Vin-La-Vry-L4-Cru [II] pri čemu:
In these combination methods, the compound will generally be given in a daily dose of 1-100 mg/kg body weight daily in conjunction with other agents. 
U ovim kombiniranim metodama, spoj formule I općenito će biti dan u dnevnoj dozi od 1-100 mg/kg tjelesne težine na dan zajedno sa drugim sredstvima.
wherein the antibody or antigen-binding fragment comprises a heavy chain variable region (HCVR) comprising heavy chain CDR1, CDR2 and CDR3 sequences of SEQ ID NO:22, 24 and 26, respectively, and a light chain variable region (LCVR) comprising light chain CDR1, CDR2 and CDR3 sequences of SEQ ID NO:30, 32 and 34, respectively wherein the chemotherapeutic agent is a platinum-based chemotherapeutic agent or a pyrimidine analogue, optionally wherein the chemotherapeutic agent is cisplatin or 5-FU; 
naznačen time, što se antitijelo ili fragment koji veže antigen sastoji od varijabilne regije teškog lanca (HCVR) koja sadrži sekvence teškog lanca CDR1, CDR2 i CDR3 sa SEQ ID NO:22, odnosno 24, odnosno 26 te varijabilne regije lakog lanca (LCVR) koja sadrži sekvence lakog lanca CDR1, CDR2 i CDR3 sa SEQ ID NO:30, odnosno 32, odnosno 34; naznačen time, što je kemoterapijsko sredstvo kemoterapijsko sredstvo na bazi platine ili analog pirimidina, pri čemu je kemoterapijsko sredstvo opcionalno cisplatin ili 5-FU;
The composition of claim 7, formulated for oral administration. The composition of claim 7, formulated as a tablet for oral administration. 
Kompozicija iz patentnog zahtjeva 3 ili 4 koja je formulirana za oralnu administraciju; izborno, koja je formulirana kao tableta.
a sequence of at least 15 amino acids N-terminally adjacent to the KEY region of the invariant chain of Seq ID No: 2 but without the KEY region itself, wherein the at least 15 amino acids are within 30 residues of the KEY region. 
(ii) slijed od najmanje 15 aminokiseline u N-terminalnom susjedstvu područja KEY nepromjenjivog lanca SEQ ID NO: 2 no bez samog područja KEY, gdje je najmanje 15 aminokiseline unutar 30 ostataka područja KEY.
In further particular embodiments of the above embodiment, L is a polyalkylene glycol linker, such as a polyethylene glycol linker. 
i Zo Spoj u skladu s patentnim zahtjevom 1, naznačen time, da L je polietilen glikol linker.
maintaining an aqueous reaction mixture comprising excess pyrophosphate and a platinum complex of the formula VI as set forth in FIG. 
(i) održavanje vodene reakcijske smjese koja sadrži višak pirofosfata i kompleks platine prema formuli V ili VI: